Aurinia Pharmaceuticals Files Proxy Supplement

TL;DR

Aurinia Pharma dropped more proxy docs for the AGM - shareholders need to check it out before voting.

AI Summary

Aurinia Pharmaceuticals Inc. filed a Definitive Additional Materials (DEFA14A) on June 4, 2024, related to its 2024 Annual General Meeting. This filing supplements previous proxy materials and concerns matters to be voted on by shareholders. The company is based in Edmonton, Alberta, Canada, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing provides shareholders with updated or additional information necessary for them to make informed voting decisions at the upcoming Annual General Meeting.

Risk Assessment

Risk Level: low — This is a routine proxy filing providing additional materials for an upcoming shareholder meeting, not indicating any immediate financial distress or significant operational change.

Key Players & Entities

• Aurinia Pharmaceuticals Inc. (company) — Registrant
• 0001600620-24-000083 (filing_id) — Accession Number
• 20240604 (date) — Filing Date
• Edmonton (location) — Company Headquarters

FAQ

Filing Documents

• combined2024defa14a_agmxci.htm (DEFA14A) — 85KB
• auph_-x2024agmcircularsu001.jpg (GRAPHIC) — 244KB
• auph_-x2024agmcircularsu002.jpg (GRAPHIC) — 78KB
• auph_-x2024agmcircularsu003.jpg (GRAPHIC) — 199KB
• auph_-x2024agmcircularsu004.jpg (GRAPHIC) — 230KB
• auph_-x2024agmcircularsu005.jpg (GRAPHIC) — 223KB
• auph_-x2024agmcircularsu006.jpg (GRAPHIC) — 221KB
• auph_-x2024agmcircularsu007.jpg (GRAPHIC) — 179KB
• auph_-x2024agmcircularsu008.jpg (GRAPHIC) — 201KB
• auph_-x2024agmcircularsu009.jpg (GRAPHIC) — 231KB
• auph_-x2024agmcircularsu010.jpg (GRAPHIC) — 261KB
• auph_-x2024agmcircularsu011.jpg (GRAPHIC) — 243KB
• auph_-x2024agmcircularsu012.jpg (GRAPHIC) — 268KB
• auph_-x2024agmcircularsu013.jpg (GRAPHIC) — 265KB
• auph_-x2024agmcircularsu014.jpg (GRAPHIC) — 244KB
• auph_-x2024agmcircularsu015.jpg (GRAPHIC) — 210KB
• auph_-x2024agmcircularsu016.jpg (GRAPHIC) — 244KB
• auph_-x2024agmcircularsu017.jpg (GRAPHIC) — 185KB
• auph_-x2024agmcircularsu018.jpg (GRAPHIC) — 222KB
• auph_-x2024agmcircularsu019.jpg (GRAPHIC) — 90KB
• 0001600620-24-000083.txt ( ) — 5647KB

From the Filing

Combined 2024 DEFA14A_AGM_Circular Supplement June 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 __________________________________________________ Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 AURINIA PHARMACEUTICALS INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box) No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies (2) Aggregate number of securities to which transaction applies (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined) (4) Proposed maximum aggregate value of transaction (5) Total fee paid Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid (2) Form, Schedule or Registration Statement No. (3) Filing Party (4) Date Filed SUPPLEMENT TO MANAGEMENT INFORMATION CIRCULAR AND PROXY STATEMENT FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 14, 2024 On or about May 3, 2024, Aurinia Pharmaceuticals Inc. (the "Company") furnished or otherwise made available to shareholders a Management Information Circular and Proxy Statement (the "Proxy Statement/Circular") describing the matters to be voted upon at our 2024 Annual General Meeting of Shareholders (the "Annual Meeting"), to be held at 12:00 p.m., Eastern Time, on June 14, 2024. This Supplement is being filed to reflect that the Company is reducing the increase in the shares reserved for issuance under the Company's Equity Incentive Plan in Proposal 4 from 11,375,000 Plan Shares (as defined in the Proxy Statement/Circular) to 8,500,000 Plan Shares. Accordingly, this Supplement revises and amends the Proxy Statement/Circular to decrease the number of Plan Shares requested to be reserved for use under our Equity Incentive Plan in Proposal 4 in the Proxy Statement/Circular from 35,190,115 to 32,315,115, representing a total increase of 8,500,000 Plan Shares, and representing, in aggregate, 22.7% of total shares outstanding as of April 30, 2024. For clarity, all references in the Proxy Statement/Circular to (i) 35,190,115 Plan Shares shall hereby be amended to reference 32,315,115 Plan Shares, (ii) 11,375,000 Plan Shares shall hereby be amended to reference 8,500,000 Plan Shares and (iii) 24.7% shall hereby be amended to reference 22.7%. In addition, Appendix C of the Proxy Statement/Circular shall hereby be amended to reflect the proposed amendment to the Equity Incentive Plan as set forth in Appendix C hereto. This Supplement should be read in conjunction with the Proxy Statement/Circular. The Plan Amendment (as defined in the Proxy Statement/Circular) was further approved by the Board on June 3, 2024. Revised Proposed Resolutions For clarity, it is proposed that at the Meeting the following revised resolution be adopted: "RESOLVED that the proposed amendment and restatement of the Company's Equity Incentive Plan, in the form attached as Appendix C to this Proxy Statement/Circular to increase the maximum fixed number of common shares reserved for issuance pursuant to the Equity Incentive Plan from 23,815,115, to 32,315,115, be approved." Additional Information Shareholders of record who have already submitted proxies for the Annual Meeting may revoke them, or if they wish to change their vote they may do so by: Online during the Meeting, follow the provided instructions to join the Meeting at https://web.lumiagm.com/415837864, starting at 12:00 p.m. Eastern Time on Friday, June 14, 2024. The password for the meeting is aurinia2024 (case sensitive). The webcast will open prior to the start of the Meeting and we recommend that you log in at least 15 minutes before the Meeting to ensure you are logged in when the Meeting begins. Mail using the proxy card, simply complete, sign and date the proxy card delivered to you and return it promptly in the envelope provided. If you return your signed proxy card to us before the Meeting by 12:00 p.m. (Eastern Time) on June 12, 2024, or no later than 48

View Full Filing

View this DEFA14A filing on SEC EDGAR